Wolverine Asset Management LLC cut its holdings in shares of Amedisys, Inc. (NASDAQ:AMED – Free Report) by 1.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,781 shares of the health services provider’s stock after selling 400 shares during the quarter. Wolverine Asset Management LLC’s holdings in Amedisys were worth $3,193,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Water Island Capital LLC grew its holdings in shares of Amedisys by 185.0% in the fourth quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock valued at $67,559,000 after purchasing an additional 461,368 shares during the period. Norges Bank acquired a new position in Amedisys in the fourth quarter valued at approximately $34,032,000. Segantii Capital Management Ltd purchased a new position in Amedisys in the fourth quarter worth approximately $32,776,000. Alpine Associates Management Inc. lifted its position in shares of Amedisys by 23.0% during the fourth quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after purchasing an additional 237,600 shares in the last quarter. Finally, Highbridge Capital Management LLC grew its holdings in shares of Amedisys by 221.5% in the fourth quarter. Highbridge Capital Management LLC now owns 225,056 shares of the health services provider’s stock valued at $21,394,000 after purchasing an additional 155,056 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company’s stock.
Wall Street Analysts Forecast Growth
AMED has been the subject of several recent research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target on the stock. in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $100.67.
Amedisys Trading Down 0.5 %
NASDAQ AMED opened at $97.52 on Wednesday. The firm’s fifty day moving average price is $97.44 and its 200 day moving average price is $94.51. Amedisys, Inc. has a 12 month low of $89.55 and a 12 month high of $98.95. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.16 and a quick ratio of 1.16. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -152.38, a price-to-earnings-growth ratio of 1.92 and a beta of 0.79.
Amedisys (NASDAQ:AMED – Get Free Report) last issued its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.10. The company had revenue of $591.19 million for the quarter, compared to analyst estimates of $579.34 million. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. On average, sell-side analysts expect that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.
Amedisys Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
- Five stocks we like better than Amedisys
- The How and Why of Investing in Gold Stocks
- Nordstrom’s Winning Formula: 3 Factors Behind the Stock’s Success
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How to See Stocks the Way Warren Buffett Sees Stocks
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 No-Brainer Stocks to Buy and Hold Long-Term
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED – Free Report).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.